Becton, Dickinson and Company (BDX)
- Previous Close
234.63 - Open
233.31 - Bid 229.10 x 1000
- Ask 234.02 x 800
- Day's Range
231.53 - 234.19 - 52 Week Range
218.75 - 269.52 - Volume
1,973,750 - Avg. Volume
1,364,995 - Market Cap (intraday)
67.491B - Beta (5Y Monthly) 0.45
- PE Ratio (TTM)
46.98 - EPS (TTM)
4.97 - Earnings Date Nov 7, 2024
- Forward Dividend & Yield 3.80 (1.63%)
- Ex-Dividend Date Sep 9, 2024
- 1y Target Est
276.27
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
www.bd.com70,000
Full Time Employees
September 30
Fiscal Year Ends
Sector
Medical Instruments & Supplies
Industry
Recent News: BDX
View MorePerformance Overview: BDX
Trailing total returns as of 9/20/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BDX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BDX
View MoreValuation Measures
Market Cap
67.82B
Enterprise Value
81.83B
Trailing P/E
47.02
Forward P/E
16.89
PEG Ratio (5yr expected)
1.08
Price/Sales (ttm)
3.45
Price/Book (mrq)
2.62
Enterprise Value/Revenue
4.13
Enterprise Value/EBITDA
18.41
Financial Highlights
Profitability and Income Statement
Profit Margin
7.13%
Return on Assets (ttm)
3.25%
Return on Equity (ttm)
5.63%
Revenue (ttm)
19.83B
Net Income Avi to Common (ttm)
1.46B
Diluted EPS (ttm)
4.97
Balance Sheet and Cash Flow
Total Cash (mrq)
5.31B
Total Debt/Equity (mrq)
74.70%
Levered Free Cash Flow (ttm)
4.43B